Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-10-10
2006-10-10
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S323000, C514S381000, C514S414000, C544S144000, C546S201000, C548S253000, C548S413000, C548S468000
Reexamination Certificate
active
07119090
ABSTRACT:
The present invention relates to novel pyrrole substituted 2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
REFERENCES:
patent: 3308134 (1967-03-01), Plostnieks
patent: 4002749 (1977-01-01), Rovnyak
patent: 4053613 (1977-10-01), Rovnyak et al.
patent: 4966849 (1990-10-01), Vallee et al.
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5302606 (1994-04-01), Spada et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
patent: 5786488 (1998-07-01), Tang
patent: 5792783 (1998-08-01), Tang
patent: 5840745 (1998-11-01), Buzzetti et al.
patent: 5880141 (1999-03-01), Tang
patent: 5883113 (1999-03-01), Tang
patent: 5883116 (1999-03-01), Tang
patent: 5886020 (1999-03-01), Tang
patent: RE36256 (1999-07-01), Spada et al.
patent: 6395734 (2002-05-01), Tang et al.
patent: 0 566 226 (1993-10-01), None
patent: 91-13055 (1991-09-01), None
patent: 91-15495 (1991-10-01), None
patent: 91/15495 (1991-10-01), None
patent: 92/20642 (1992-11-01), None
patent: 92-20642 (1992-11-01), None
patent: 92/21660 (1992-12-01), None
patent: 92-21660 (1992-12-01), None
patent: 94/03427 (1994-02-01), None
patent: 94-03427 (1994-02-01), None
patent: 94/14808 (1994-07-01), None
patent: 94-14808 (1994-07-01), None
patent: 96/40116 (1996-12-01), None
patent: 96-40116 (1996-12-01), None
patent: 98-07695 (1998-02-01), None
patent: 98/07695 (1998-02-01), None
patent: 98/24432 (1998-06-01), None
patent: 98/38984 (1998-09-01), None
patent: 99/61422 (1999-02-01), None
patent: 99/48868 (1999-09-01), None
Sun, et al. “Design, Synthesis, and Evaluation of Substituted 3-(3-or 4-Carbonxyethylpyrrol-2-yl)methylidenyl}indolin-2-ones as Inhibitors of VEGF, FGF, and PDGF Receptor Tyrosine Kinases,”J. Med. Chem. 42:5120-5130 (1999) ©American Chemical Society.
Database Caplus on STN, AN 1998: 147306, abstract for Tang et al., Indolinone combinatorial libraries and related products and methods for the treatment of disease, WO 98/07695 (Feb. 26, 1998).
Database Caplus on STN, AN 1997: 140244, abstract for Tang et al., Indolinone compounds capable of modulating tyrosine kinase signal transduction, WO 96/40116 (Dec. 19, 1996).
Akbasak et al., “Oncogenes: cause of conquence in the development of glial tumors,”J. Neurol, Sci. 111:119-133 (1992).
Arteaga et al., “Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice,”J. Clin. Invest.84:1418-1423 (1989).
Arvidsson et al., “Tyr-716 in the Platelet-Derived Growth Factor β-Receptor Kinase Insert is Involved in GRB2 Binding and Ras Activation,”Molecular and Cellular Biology14:6715-6726 (1994).
Baserga, “Oncogenes and the Strategy of Growth Factors,”Cell79:927-930 (1994).
Baserga, “The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?”Cancer Research55:249-252 (1995).
Bolen et al., “The Src family of tyrosine protein kinases in hemopoietic signal transduction,”FASEB J, 6:3403-3409 (1992).
Bolen, “Nonreceptor tyrosine protein kinases,”Oncogene8:2025-2031 (1993).
Bonner et al., “Structure and Biological Activity of Human Homologs of theraf/milOncogene,”Molecular and Cellular Biology5:1400-1407 (1985).
Cance et al., “Novel Protein Kinases Expressed in Human Breast Cancer,”Int. J. Cancer54:571-577 (1993).
Claesson-Welsh, “Signal Transduction by the PDGF Receptors,”Progress in Growth Factor Research5:37-54 (1994).
Coppola et al., “A Functional Insulin-Like Growth Factor I Receptor is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor,”Molecular and Cellular Biology14:4588-4595 (1994).
De Vries et al., “Thefms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor,”Science255:989-991 (1992).
Decker et al., “A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity,”Journal of Immunological Methods15:61-69 (1988).
Dickson et al., “Tyrosine kinase receptor—nuclear protooncogene interactions in breast cancer,”Cancer Treatment Res.61:249-273 (1992).
Fantl et al., “Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules That Mediate Different Signaling Pathways,”Cell69:413-423 (1992).
Ferrara and Henzel, “Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells,”Biochemical and Biophysical Research Communications161:851-858 (1989).
Fingl and Woodbury, “Chapter 1—General Principles,” inThe Pharmacological Basis of Therapeutics5th edition, Goodman and Gilman editors, MacMillan Publishing Co., Inc., New York, pp. 1-46 (1975).
Folkman and Shing, “Angiogenesis,”J. Biol. Chem.267:10931-10934 (1992).
Folkman, “Ch. 24. Angiogenesis,”Congress of Thrombosis and Haemostasis(Verstraete et al., eds.) Leuven University Press, Leuven pp. 583-596 (1987).
Folkman, “Tumor Angiogenesis, Therapeutic Implications,”New England J. Medicine285:1182-1186 (1971).
Folkman, “What is evidence that tumors are angiogenesis dependent?” Journal of National Cancer Institute 82:4-6 (1990).
Gennaro (editor),Remington's Pharmaceutical Sciences(1990) ( Table of Contents Only).
Goldring and Goldring, “Cytokines and Cell Growth Control,”Critical Reviews in Eukaryotic Gene Expression1:301-326 (1991).
Honegger et al., “Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Activity and Alters Cellular Routing,”Cell51:199-209 (1987).
Houck et al., “Dual Regulation of Vascular Endothelial Growth Factor Bioavailabilty by Genetic and Proteolytic Mechanisms,”J. Biol. Chem.267:26031-26037 (1992).
Hu et al., “Interaction of Phosphatidylinositol 3-Kinase-Associated p85 with Epidermal Growth Factor and Platelet-Derived Growth Factor Receptors,”Molecular and Cellular Biology12(3):981-990 (1992).
Jellinek et al., “Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor,”Biochemistry33:10450-10456 (1994).
Kashishian and Cooper, “Phosphorylation Sites at the C-terminus of the Platelet-Derived Growth Factor Receptor Bind Phospholipase Cγ1,”Molecular Biology of the Cell4:49-57 (1993).
Kashishian et al., “Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and PI3 kinasein vivo,”The EMBO Journal11(4):1373-1382 (1992).
Kendall and Thomas, “Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor,”Proc. Natl. Acad. Sci. USA90:10705-10709 (1993).
Kim et al., “Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growthin vivo,”Nature362:841-844 (1993).
Kinsella et al., “Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel,”Exp. Cell Research199:56-62 (1992).
Klagsbrun and Soker, “VEGF/VPF: the angiogenesis factor found?”Current Biology3:699-702 (1993).
Koch et al., “SH2 and SH3 Domains: Elements That Control Interactions of Cytoplasmic Signaling Proteins,”Science252:668-674 (1991).
Komada and Kitamura, “The cell dissociation and motility triggered by scatter factor/hepatocyte growth factor are mediated through the cytoplasmic domain of the c-Met receptor,”Oncogene8:2381-2390 (1993).
Korc et al., “Overexpression of the Epidermal Growth Factor Receptor in Human Pancreatic Cancer is Associated with Concomitant Increases in the Levels of Epidermal Growth Factor and Transforming Growth Factor Alpha,&#x
McMahon Gerald
Sun Li
Tang Peng Cho
Burrous Beth A.
Foley & Lardner LLP
Saeed Kamal A.
Sugen Inc.
LandOfFree
Pyrrole substituted 2-indolinone protein kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrole substituted 2-indolinone protein kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrole substituted 2-indolinone protein kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3622923